Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
MaaT Pharma H1 operating loss widens 29% to EUR 19 million; revenue drops 55% to EUR 1.08 million

MaaT Pharma H1 operating loss widens 29% to EUR 19 million; revenue drops 55% to EUR 1.08 million

BitgetBitget2026/09/29 16:03
  • MaaT Pharma posted H1 2026 revenue down 56% to EUR 1.08 million, while net loss widened 22% to EUR 18.33 million.
  • R&D expenses climbed 30% to EUR 19.2 million, while operating loss widened 29% to EUR 19 million.
  • Cash and cash equivalents fell to EUR 17.1 million at June 30, 2026, from EUR 24.9 million at Dec. 31, 2025.
  • Management said cash-preservation measures extend its cash runway to December 2026, and it is exploring financing and partnerships.
  • CHMP maintained its negative opinion on MaaT013’s conditional marketing application; MaaT Pharma proposed the PHOENIX Phase 3 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maat Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260929450566) on September 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16